Zymeworks is a privately held biotechnology company developing proprietary biocatalyst (enzyme) engineering technologies to create novel process development solutions for industrial, specialty chemical and pharmaceutical manufacturing. The cornerstone of Zymeworks' science & technology is its unique molecular modeling platform that enables the company to accurately simulate the physical and chemical properties of enzymes.
News on Zymeworks Inc
Zymeworks has raised a US$ 61.5 million Series A mezzanine financing to support the advancement of its Azymetric therapeutics pipeline. The financing was supported by a syndicate of U.S. and... more
Vancouver's Zymeworks announced today the completion of a $8.1 Million financing round. The financing consists of a follow-on round of institutional investment by Montreal's CTI Life... more
Business magazine BCBusiness's latest issue reveals what it believes to be our country's top 20 most innovative companies this year. Topping the list is the City of Vancouver, with its... more